1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
BioSyent Inc.

BioSyent Inc.

RX.V
BioSyent Inc.CA flagToronto Stock Exchange Ventures
14.57
CAD
+0.07
- -
166.66MMarket Cap
BioSyent Inc.
RX.V
(Toronto Stock Exchange Ventures)

Recent

price

14.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.13
0.22
0.39
0.58
0.89
1.11
1.25
1.44
1.48
1.54
1.72
2.26
2.27
2.64
3.11
3.82
4.08
Revenue per Share
- -
0.03
0.12
0.14
0.23
0.27
0.3
0.36
0.39
0.31
0.29
0.5
0.44
0.54
0.64
0.8
0.8
Basic EPS, GAAP
- -
0.05
0.09
0.15
0.26
0.12
0.28
0.41
0.4
0.26
0.52
0.36
0.36
0.41
0.35
0.77
1.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.04
0.16
0.18
0.2
0.2
Dividend per Share
-0.51
0.08
0.21
0.34
0.58
0.84
1.12
1.49
1.84
1.77
1.96
2.36
2.54
2.73
2.93
3.51
3.84
Book Value per Share
0.05
0.09
0.22
0.36
0.59
0.8
1.08
1.42
1.77
1.78
1.99
2.42
2.61
2.81
2.66
3.26
1.72
Tangible Book Value per Share
12
13
13
14
14
14
14
14
15
14
13
13
12
12
11
11
11
Basic Weighted Avg Shares
2
3
5
8
12
15
18
21
22
21
22
29
28
32
35
43
46
Sales/Revenue/Turnover
6.87
18.03
27.63
31.06
33.56
32.91
32.18
31.76
31.67
29.72
22.95
28.82
24.73
23.85
25.88
26.28
25.69
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
2
2
3
4
4
5
6
4
4
6
5
6
7
9
9
Net Income, GAAP
- -
- -
- -
21.4
27.1
27.12
26.58
24
24.4
25.57
27.53
25.03
26.54
24.3
25.68
25.09
25.68
Effective Tax Rate (%)
2.88
14.97
30.68
24.72
25.83
24.47
24.05
25.08
26.5
20.39
16.99
21.95
19.55
20.45
20.75
20.93
19.65
Profit Margin (%)
1
1
3
4
8
11
15
20
25
23
25
30
31
30
19
33
15
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
1
1
1
1
1
1
LT Debt
1
1
3
5
8
12
17
22
28
26
27
32
33
35
35
41
45
Total Equity
18.06
55.25
- -
46.24
42.88
34.89
28.72
25.59
20.56
17.01
13.14
19.96
14.86
16.03
18.58
21.42
19.67
Return on Invested Capital (%)
-1.94
-15.83
- -
52.61
50.34
38.52
31.02
27.66
23.69
16.53
14.39
21.64
17.19
19.57
21.53
24.33
21.64
Return on Capital (%)
- -
- -
84.05
52.61
50.34
38.52
31.02
27.66
23.69
17.03
15.14
22.68
17.84
20.21
22.14
24.85
23.25
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
4
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
130
143
163

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
36
40
31
Cash, Cash Equivalents & STI
23
29
11
Accounts Receivable, Net
6
4
7
Inventories
6
6
11
Total Current Liabilities
7
7
17
Payables & Accruals
7
7
9
ST Debt
- -
- -
4
Deferred Revenue
- -
- -
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.89%
9.37%
18.46%
Free Cash Flow
30.52%
14.54%
115.82%
Net Income, GAAP
11.56%
21.45%
23.96%
Sales/Revenue/Turnover
11.24%
14.53%
22.9%
Total Cash Common Dividend
- -
- -
8.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
9
10
9
35
2025
11
10
12
10
43
2026
14
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.14
0.2
- -
0.64
2025
0.21
0.18
0.24
0.18
0.8
2026
0.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
0.04
- -
0.18
2025
0.05
0.05
0.05
0.05
0.2
2026
0.05
- -
- -
- -
- -
Similar Companies
Clicks Group Limited (CLS.JO)
Gennex Laboratories Limited (GENNEX.BO)
Praveg Ltd. (PRAVEG.BO)
High Tide Inc. (2LYA.F)
Mera Pharmaceuticals, Inc. (MRPI)
Noveris Health Sciences Inc. (MYCOF)
Business
BioSyent Inc. (TSX-V: RX) is a Canadian specialty pharmaceutical company focused on the commercialization of specialty pharmaceutical products in Canada and internationally, specializing in products for rare diseases, endocrinology, dermatology, and gastroenterology. The company offers a portfolio of branded products including FeraMAX Pd (iron supplement), Teverel (tacrolimus ointment for atopic dermatitis), Lupron Depot-Ped (leuprolide acetate for central precocious puberty), MenaQ7 (vitamin K2 supplement), and Jaundice Meter (non-invasive bilirubin measurement device), among others; it provides services such as market access support, medical education, and distribution partnerships for niche therapeutics. Founded in 2006 and headquartered in Mississauga, Ontario, BioSyent operates primarily in Canada with select international distribution agreements in over 20 countries across North America, Europe, Asia, and the Middle East, targeting healthcare professionals, hospitals, and patients with unmet medical needs in specialized therapeutic areas. In recent developments, BioSyent completed the acquisition of the Canadian rights to Sybravo (calcitonin salmon nasal spray) from Upjohn in late 2024, expanding its endocrinology portfolio; the company also secured a strategic distribution partnership with Avera Pharmaceuticals for FeraMAX Pd Therapeutic Iron in the U.S. in early 2025, marking its first major U.S. market entry. Additionally, BioSyent launched its updated digital jaundice management platform integrating the BiliCam app with JM-105 Jaundice Meters across Canadian pediatric centers in mid-2025, enhancing non-invasive neonatal care solutions. These moves reflect ongoing portfolio expansion and operational growth, with no reported reorganizations or name changes in the last two years.